Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-015766
Filing Date
2023-05-04
Accepted
2023-05-04 16:20:39
Documents
61
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ngm-20230331.htm   iXBRL 10-Q 1347813
2 EX-10.1 ngm-20230331x10qex101.htm EX-10.1 26163
3 EX-31.1 ngm-20230331x10qex311.htm EX-31.1 11191
4 EX-31.2 ngm-20230331x10qex312.htm EX-31.2 10949
5 EX-32.1 ngm-20230331x10qex321.htm EX-32.1 8129
  Complete submission text file 0001628280-23-015766.txt   5838706

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20230331.xsd EX-101.SCH 35367
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ngm-20230331_cal.xml EX-101.CAL 46595
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ngm-20230331_def.xml EX-101.DEF 173477
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20230331_lab.xml EX-101.LAB 500952
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20230331_pre.xml EX-101.PRE 307162
55 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20230331_htm.xml XML 864846
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38853 | Film No.: 23889090
SIC: 2834 Pharmaceutical Preparations